• A patient with chronic lymphocytic leukemia and severe and frequently recurring herpes labialis received oral acyclovir for more than 18 months, during most of this period at a low dosage (400 mg/d). This regimen was fully successful in preventing recurrences, with no adverse effects.
(Arch Intern Med 1986;146:1438-1440)
Dan M, Siegman-Igra Y, Weinberg M, Michaeli D. Long-term Suppression of Recurrent Herpes Labialis by Low-Dose Oral Acyclovir in an Immunocompromised Patient. Arch Intern Med. 1986;146(7):1438–1440. doi:10.1001/archinte.1986.00360190230035
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.